In line with our findings, a number of compounds (such as umbelliferone, phosphocreatine, taxifolin, and losartan) have been shown to mitigate DCM by suppressing the JAK2/STAT3 pathway [44,45]. The gene discussed is JAK2; the disease is familial dilated cardiomyopathy.